Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Next Friday will be like a Christmas bonus. Not sure how much you will get but you know it will be more than nothing!
LeddachJack
Completely agree with you mate, always better to have something rather than nothing.
Aspen
the shareholders list (page 5,7 of the prospectus) does not give the impression that any of them is selling on admission. Most of them are Universities, charity research funds etc). AG as far as i understand is not selling anytime soon, he is not here for 20% or so, he will prbly exercise his warrants which will add cash to the company. So to a large extent the sp on admission is more or less controlled by us PIs. There are a lot of other investors waiting to buy on admission, so If we do not sell, the sp rises, simple. We waited long time, why not give it 3-6 months frame, remember iqai from 1 to 14 (yes 14x) within 6m 2019 while awaiting for certification and fda?
As from 8.00AM 14th, we need to look at the bigger picture going forward, why wait all this time and then not give BOU/CIZZ the chance to develop.
Aspen
Agreed.
I've sat on the AIM darling of 2015 - XTR for 6 years waiting for it to come good - green shoots this year! :-)
We will be listed at 80% discount then other biotech companies that’s one of the many reasons I have few bob prepared for next week Friday. Quiet confident we will rise significantly. Only one co in the world has the test for a lung cancer it’s CIZZLE! Potential is no brainer. Apart from this I’m still ****ed that we waited so long in this nightmare and we didn’t make it 10 or 20 bags straight like we all dreamed but we will soon. I could write poems how I’m annoyed but it won’t change anything. Looking forward for a listing day it will be a really positive and exciting day! GL all
80 % discount to peers ..that says to me get some " have cash ready " for the first day trading !
80% discount means 500% upside potential, not counting the potential for takeover or JV and other future developments. I do expect the first day of trading will be the lowest price you will get with news flow on many milestones, (Manufacturing partner, currently in discussion, Licencing partner, CE, FDA approval, NHS collaboration). That is short/medium term.
However, if this turns to be the "biomarker of choice" for Lung Ca. similar to PSA for prostate Ca or CEA for bowel Ca; both developed to be THE mainstream tests for screening, follow up after treatment. Then, we will have a breakthrough medical discovery, sky is the limit (no hype, only scientific here), hence the multiple global patents.
p.s. Neil, since you started your journey through the medical journals, here is a little Sund. present, only a 5min read -:),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832880/
Just shows the potential, enjoy the rest of W/E
We could have a nice surprise waiting for us at 7.00AM 14th, a RNS with some information about the company which they have not wanted to release until then, just to give the sp a nice little boost.
Aspen
We will get a great one 100% it will mention readmission
Presentation:
https://www.youtube.com/watch?app=desktop&v=EUfqP-9eaSM
Thanks TRA1,
There are a surprising number of papers by Dr Coverley and co authors on this research, in addition to other authors. So i will never even hope to find/read them all. This quote stood out in one of them though.......
"Conclusions. Unexpected and unusual molecular structure of CIZ1b in native plasma has complicated immunoassay design, and delayed translation of this promising biomarker. However, CIZ1b can now be measured using a high-throughput, hospital-friendly sandwich ELISA format, overcoming an important barrier to further clinical development and application of this blood test for early stage lung cancer."
Dr Coverley is clearly a very intelligent person, and this is her life's work.
Your previous comments re shareholding also caught my attention.
You are quite correct in that the big holders are funds etc. In my business, i have had dealings with Finance Yorkshire (now known as Mercia) on a number of occasions, and it is quite telling that they elected to take an equity stake in CIZ, and a fair sized one at that, rather than a purely capital/interest repayment schedule.
Their eligibility criteria requirement for this type of investment means they are expecting a significant return.
Speaking on a purely personal level, I,m not really so interested in what the share price will be on Friday, as it will be influenced by
1.The new listing
2. Day traders buying in and selling immediately
3. Existing holders that just want their money back after such a long time in suspension etc.
I am far more interested in where this is going over a longer term.
Neil
Well i guess this is Allan Syms reason for talking to China.
Extracts taken from Hindawi BioMed Research International
[1]. Lung cancer is not only the most common cancer in the world, but also the primary reason for death due to cancer [1]. At present, the number of Chinese patients who were newly diagnosed with lung cancer is about 500 thousand each year, and the number is expected to reach one million by 2025
[3]. Currently, the most often used treatments for NSCLC are surgery, radiotherapy, and chemotherapy, in which the complete surgical resection is the most effective method [4]. Despite the improvements of surgical techniques and instruments in recent years, the overall 5-year survival rate for NSCLC patients after surgery is from 15% to 45% [6]. On the other hand, most patients that were diagnosed with NSCLC were already in the unresectable stage of IIIB or IV and the option of surgery treatment was not feasible, which is the main reason why the overall 5-year survival rate of NSCLC patients is only 12%. However, the overall 5-year survival rate can be increased to 50% if patients can be diagnosed in an early stage
[6]. Currently, the diagnosis of NSCLC mainly depends on X-ray, CT, sputum cytology, fiber bronchoscopy, and cellular pathology. However, X-ray is not sensitive to small lesions and covert lesions; sputum cytology only works on lung cancer originated in the center of airways and has a low detection rate; fiber bronchoscopy is not suitable for early diagnosis due to its invasiveness; cellular pathology cannot precisely determine malignance stages [7]. As such, identifying molecular biomarkers for early diagnosis of NSCLC is urgently needed.
Literature review of the top predicted gene biomarkers suggested that most of them were already considered critical for development of NSCLC.
CIZZLE has the technology to help lung cancer sufferers by increasing the 5 year survival rate by 400% !!!
Neil